Here, we also show that the CysLT1 antagonist blocks PLY-dependent ALI both in BLT2-KO mice and in NSAIDs-pretreated mice, suggesting that the CysLT1 antagonist is a candidate drug for treating severe ALI in patients with pneumococcal pneumonia. This evidence concerns the gene CYSLTR1 and pneumococcal pneumonia.